Probiotic stock solution capable of producing folic acid and SOD (superoxide dismutase) and having functions of reducing uric acid and reducing blood sugar and preparation method of probiotic stock solution

Abstract

The invention relates to a probiotic stock solution capable of producing folic acid and SOD (superoxide dismutase) and having the functions of reducing uric acid and reducing blood sugar and a preparation method of the probiotic stock solution. Existing probiotic products are inconvenient to eat and do not have the effects of producing folic acid and SOD (superoxide dismutase). The probiotic stock solution contains the bifidobacterium animalis fermentation liquor, the lactobacillus paracasei fermentation liquor, the lactobacillus casei fermentation liquor, the lactobacillus fermentum fermentation liquor, the lactobacillus rhamnosus fermentation liquor and the lactobacillus reuteri fermentation liquor, and the final product is in a liquid state, can be packaged by small strip bags, and is relatively convenient to refrigerate, store and use. The probiotic stock solution disclosed by the invention not only has the effects of reducing uric acid and reducing blood sugar, but also generates water-soluble vitamin folic acid and superoxide dismutase SOD in the preparation and fermentation process, has the effects of resisting oxidation and aging after being taken into a human body, is suitable for pregnant women to take, and can reduce the risk of fetal neural tube defect.

Description

Technical Field

[0001] The invention relates to a probiotic stock solution, in particular to a probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar, and a preparation method thereof. Background Art

[0002] After probiotics enter the gastrointestinal environment, they can quickly begin to multiply and colonize in the intestines, gradually competing with pathogens for living space and nutrients, squeezing out pathogens from resources, and then inhibiting their growth. In addition, probiotics can also stimulate the human intestinal immune system to secrete immune factors, allowing immune cells and probiotics to form a healthy balance and resist the invasion of pathogens.

[0003] Probiotic drinks can facilitate the intake of probiotics, but most of the current probiotic drinks are made of solid probiotics as raw materials, which are made into liquid by adding water. This method of use makes them not directly edible and the taste is also poor. In addition, the current probiotic drinks have a single function. Although they have the effect of lowering blood sugar, there is still room for further research and development. Summary of the invention

[0004] The purpose of the present invention is to provide a probiotic stock solution which produces folic acid and SOD and has the functions of lowering uric acid and blood sugar, and a preparation method thereof, so as to solve the problems that the current solid probiotic products are inconvenient to use and have a single function.

[0005] In order to achieve the above object, the technical solution adopted by the present invention is:

[0006] Provided is a probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar. The probiotic stock solution comprises Bifidobacterium animalis XIMC-002 fermentation liquid, Lactobacillus paracasei XIMC-001 fermentation liquid, Lactobacillus casei XIMC-003 fermentation liquid, Lactobacillus fermentum XIMC-009 fermentation liquid, Lactobacillus rhamnosus XIMC-6 fermentation liquid and Lactobacillus reuteri XIMC-30 fermentation liquid.

[0007] Furthermore, the animal Bifidobacterium XIMC-002 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number of CGMCC NO.22522;

[0008] The Lactobacillus paracasei XIMC-001 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number of CGMCC NO.22521;

[0009] The Lactobacillus casei XIMC-003 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22524;

[0010] The fermented Lactobacillus XIMC-009 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22525;

[0011] The Lactobacillus rhamnosus XIMC-6 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on November 22, 2021, with the deposit number CGMCC NO.23954;

[0012] The Lactobacillus reuteri XIMC-30 was deposited in the General Microbiology Center of the China Microorganism Culture Collection Administration on May 22, 2023, with the deposit number CGMCC NO.27396.

[0013] Furthermore, the probiotic stock solution also contains Lactobacillus plantarum XIMC-005 fermentation liquid and Lactobacillus gesneri XIMC-011 fermentation liquid.

[0014] Furthermore, the Lactobacillus plantarum XIMC-005 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22526;

[0015] The formative Lactobacillus XIMC-011 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22523.

[0016] On the other hand, a method for preparing a probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar is provided, the method comprising:

[0017] Using a fermentation medium containing beans to culture various strains, the various strains include Bifidobacterium animalis XIMC-002, Lactobacillus paracasei XIMC-001, Lactobacillus casei XIMC-003, Lactobacillus fermentum XIMC-009, Lactobacillus rhamnosus XIMC-6 and Lactobacillus reuteri XIMC-30, and fermenting to obtain fermentation liquid;

[0018] Mix all the fermentation liquids and stir them evenly to obtain a mixed liquid;

[0019] The mixed liquid is divided into small strips to obtain the finished product, which is then refrigerated for storage.

[0020] Furthermore, the various strains also include Lactobacillus plantarum XIMC-005 and Lactobacillus formatus XIMC-011.

[0021] Further, various strains are cultured using fermentation medium containing beans, including:

[0022] The strain was inoculated into MRS culture solution and placed in an incubator for culture to obtain seed solution;

[0023] Sterilizing fermentation media containing legumes;

[0024] The seed liquid is poured into a sterilized fermentation medium containing beans and water, and fermented to obtain a fermentation liquid.

[0025] Further, the formula of MRS culture medium is:

[0026] Potassium dihydrogen phosphate 0.2-0.4%;

[0027] Diammonium hydrogen phosphate 0.1~0.3%;

[0028] Sodium acetate 0.5-0.8%;

[0029] Magnesium sulfate 0.02-0.04%;

[0030] Manganese sulfate 0.003~0.007%;

[0031] Tween 80 0.01~0.05%;

[0032] The rest is water.

[0033] Further, the formula of the fermentation medium containing beans is:

[0034] Beans 2-3%;

[0035] Yeast extract powder 0.4-0.8%;

[0036] Glucose 2-3%;

[0037] The rest is water.

[0038] Furthermore, the beans are selected from soybeans, black beans, adzuki beans, and mung beans.

[0039] Compared with the prior art, the present invention has the following beneficial effects:

[0040] The present invention provides a probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar, and a preparation method thereof, comprising fermented liquids of various strains, and the final product is in a liquid state, can be packaged in small strips, and stored in a refrigerator, and is convenient to sell, store, and use. In addition, the probiotic stock solution of the present invention not only has the effects of lowering uric acid and blood sugar, but also produces water-soluble vitamin folic acid and superoxide dismutase SOD during the preparation and fermentation process, has antioxidant and anti-aging effects after being ingested by the human body, and is suitable for pregnant women to take, and can reduce the risk of neural tube defects in the fetus. DETAILED DESCRIPTION

[0041] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The preferred embodiments of the present invention are given in the description. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present invention more thoroughly understood.

[0042] In the description of the present invention, it is to be understood that all the techniques and scientific terms used have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs. When there is a contradiction, the definition in this specification shall prevail. If not otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art, the reagents used in the embodiments are commercially available products, and the devices used in the embodiments are existing devices, and the limitation of means, reagents or devices cannot be understood as limitation of the present invention, and the means, reagents or devices for solving the same technical problems of the same type are within the protection scope of the present invention.

[0043] In the description of the present invention, it is to be understood that when the amount, concentration, or other value or parameter of a substance is expressed as a range, a preferred range, or a range limited by a series of upper preferred values ​​and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. When a numerical range is described in this article, unless otherwise stated, the range is intended to include its end value and all integers and fractions within the range.

[0044] It should also be noted that although the order of steps is mentioned in the method description, in some cases, they may be performed in an order different from that shown here, and this should not be construed as a limitation on the order of the steps.

[0045] The present invention provides a probiotic stock solution which produces folic acid and SOD and has the functions of lowering uric acid and blood sugar. The product is in liquid state, which is convenient for taking and storing. While having the functions of lowering uric acid and blood sugar, folic acid and SOD are also produced during the preparation and fermentation process, thereby further enriching the efficacy of the probiotic stock solution.

[0046] The probiotic stock solution comprises Bifidobacterium animalis XIMC-002 fermentation liquid, Lactobacillus paracasei XIMC-001 fermentation liquid, Lactobacillus casei XIMC-003 fermentation liquid, Lactobacillus fermentum XIMC-009 fermentation liquid, Lactobacillus rhamnosus XIMC-6 fermentation liquid and Lactobacillus reuteri XIMC-30 fermentation liquid.

[0047] in:

[0048] The animal Bifidobacterium XIMC-002 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22522;

[0049] The Lactobacillus paracasei XIMC-001 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number of CGMCC NO.22521;

[0050] The Lactobacillus casei XIMC-003 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22524;

[0051] The fermented Lactobacillus XIMC-009 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22525;

[0052] The Lactobacillus rhamnosus XIMC-6 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on November 22, 2021, with the deposit number CGMCC NO.23954;

[0053] The Lactobacillus reuteri XIMC-30 was deposited in the General Microbiology Center of the China Microorganism Culture Collection Administration on May 22, 2023, with the deposit number CGMCC NO.27396.

[0054] In addition, the probiotic stock solution also contains Lactobacillus plantarum XIMC-005 fermentation liquid and Lactobacillus gasseri XIMC-011 fermentation liquid.

[0055] in:

[0056] The Lactobacillus plantarum XIMC-005 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22526;

[0057] The formative Lactobacillus XIMC-011 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22523.

[0058] The method for preparing the probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar specifically comprises the following steps:

[0059] S1: Using a fermentation medium containing beans to culture various strains, the various strains include Bifidobacterium animalis XIMC-002, Lactobacillus paracasei XIMC-001, Lactobacillus casei XIMC-003, Lactobacillus fermentum XIMC-009, Lactobacillus rhamnosus XIMC-6 and Lactobacillus reuteri XIMC-30, and fermentation to obtain fermentation liquid.

[0060] The various strains also include Lactobacillus plantarum XIMC-005 and Lactobacillus formatus XIMC-011.

[0061] S101: Take out the strain with an inoculating loop and place it into a triangular flask with MRS culture medium, and culture it in an incubator to obtain seed solution.

[0062] The formula of MRS culture medium is:

[0063] Potassium dihydrogen phosphate 0.2-0.4%;

[0064] Diammonium hydrogen phosphate 0.1~0.3%;

[0065] Sodium acetate 0.5-0.8%;

[0066] Magnesium sulfate 0.02-0.04%;

[0067] Manganese sulfate 0.003~0.007%;

[0068] Tween 80 0.01~0.05%;

[0069] The rest is water.

[0070] The container for obtaining the seed liquid is a seed tank, which needs to be sterilized at 120-122℃ for 10-20 minutes to ensure that the seed liquid is not contaminated by bacteria. After sterilization, it should be cooled to 37-40℃ as soon as possible for transplanting.

[0071] S102: sterilizing the fermentation medium containing beans.

[0072] The formulation of the fermentation medium containing legumes is:

[0073] Beans 2-3%;

[0074] Yeast extract powder 0.4-0.8%;

[0075] Glucose 2-3%;

[0076] The rest is water.

[0077] The beans are selected from soybeans, black beans, adzuki beans and mung beans. The beans can be mixed in equal amounts, cleaned with drinking water, soaked in water for 6-16 hours (adjust the soaking time according to the season) or boiled for 5-10 minutes, and then ground with a grinder to obtain soybean milk for later use.

[0078] The fermentation medium containing beans is placed in the fermentation tank and sterilized at a temperature of 120-122°C for 10-20 minutes to ensure that the fermentation liquid is free of contamination by foreign bacteria. After sterilization, it should be cooled to 37-40°C as soon as possible for transplanting.

[0079] S103: pouring the seed liquid into a sterilized fermentation medium containing beans and water, and fermenting to obtain a fermentation liquid.

[0080] Fermentation uses a preparation tank and needs to be pasteurized at a temperature of 63-65°C and a sterilization time of 30 minutes.

[0081] The specific process of fermentation culture is as follows: first, the seed liquid in the incubator is aseptically sampled for microscopic examination and inoculation is performed. The sealing cover of the inoculation port is unscrewed, and an inoculation flame ring is placed at the inoculation port. After the flame ring is ignited, the inoculation cover is opened and the seed liquid is poured into the tank. After completion, the inoculation cover is tightened, sterile air is passed through the tank, and the pressure, heat, stirring and culture are maintained. The fermentation time is 15-20 hours and the fermentation temperature is 35-39°C. After the fermentation bacteria are cultured, samples are taken to measure the number of live bacteria.

[0082] S2: All fermentation broths are mixed and stirred evenly to obtain a mixed broth. All fermentation broths can be mixed in equal amounts and stirred evenly.

[0083] S3: Pack the mixed liquid into small strips to obtain the finished product, and store it in a refrigerator.

[0084] The following is an experimental description of the probiotic stock solution of the present invention, which has the effect of lowering uric acid:

[0085] 1 Experimental Purpose

[0086] 1.1 Detect the uric acid-lowering effect of probiotic stock solution.

[0087] 1.2 The most common method for treating hyperuricemia is to take chemically synthesized drugs, but long-term use can easily cause toxic side effects such as allergies, gastrointestinal reactions, bone marrow suppression, and liver damage. Therefore, the development of food-derived, low-toxic uric acid-lowering substances has important clinical significance.

[0088] 2 Experimental Principle

[0089] At present, the research on uric acid lowering activity at home and abroad focuses on the screening of xanthine oxidase (XOD) inhibitors. XOD is a key enzyme in the production of uric acid in the body. Inhibitors targeting XOD can directly bind to the XOD molybdenum pterin catalytic active center to block the production of uric acid. Probiotics, as an important physiological bacterial community in the intestine, have many beneficial effects such as regulating immunity. At present, studies at home and abroad have shown that lactic acid bacteria have the effect of assisting in lowering uric acid. This experiment reduces uric acid content by inhibiting the activity of XOD.

[0090] 3. Reagents and equipment required for the experiment

[0091]

[0092] 4 Experimental methods

[0093] Preparation of purine oxidase solution: Dissolve xanthine oxidase in 0.2 mol / L phosphate buffer (PBS) (pH 7.5) to 0.1 u / mL and store at 4°C.

[0094] Preparation of xanthine substrate: The substrate xanthine was first dissolved by ultrasonication with a small amount of 0.1 mol / L NaOH solution, and then fixed to a volume of 2 mmol / L xanthine substrate solution with 0.2 mol / L PBS (pH 7.5).

[0095] Add 50 μL of the sample to be tested and 50 μL of 0.02 U / mL xanthine oxidase solution to a 96-well plate, mix well at room temperature, then add 150 μL of 0.48 mmol / L xanthine solution, shake for 30 seconds, keep warm at 25°C for 25 minutes, and measure the absorbance at 290 nm. Allopurinol was used as a positive control.

[0096]

[0097] Where:

[0098] D: purine oxidase inhibition rate, %;

[0099] A1: absorbance value of added sample solution;

[0100] A2: absorbance value of sample solution without enzyme;

[0101] A3: Use buffer solution instead of the absorbance value of the sample solution;

[0102] A4: Use buffer solution instead of the absorbance of the enzyme and sample solutions.

[0103] 5 Experimental data and processing

[0104] 1 2 3 average value Probiotics stock solution 62.00％ 94.49％ 94.90％ 83.80％ Allopurinol 86.59％ 83.64％ 81.40％ 83.87％

[0105] 6 Experimental results

[0106] Allopurinol was selected as a positive control in this experiment. The XOD inhibition rate of the probiotic stock solution in this experiment was 83.80%, which was compared with the XOD inhibition rate of allopurinol in this experiment of 83.87%, which confirmed that the probiotic stock solution has the effect of lowering uric acid. (Taking the XOD inhibition rate of allopurinol as the benchmark value, the XOD inhibition rate of the probiotic stock solution was 99.92%.)

[0107] The following is an experimental description of the probiotic stock solution of the present invention, which has the effect of lowering blood sugar:

[0108] 1 Experimental Purpose

[0109] To test the blood sugar lowering effect of probiotic solution.

[0110] 2 Experimental Principle

[0111] With the development of high-throughput sequencing technology, the whole genome of lactic acid bacteria has also been gradually understood. People have found that lactic acid bacteria contain a large number of genes encoding carbohydrate-active enzymes, which mainly include enzyme families related to the degradation, modification and generation of glycosidic bonds. Studies have shown that α-amylase and α-glucosidase in diabetic patients are the main reasons for their high blood sugar levels. Lactic acid bacteria can act as a "metabolic filter" to control the absorption and decomposition of glucose by regulating the activity of related enzymes in the body, and at the same time produce a large number of short-chain fatty acids such as acetic acid and propionic acid and metabolites such as glucan. For example, the regulation of α-glucosidase and α-amylase delays the absorption process of carbohydrates, thereby reducing blood sugar concentration and slowing down the demand for sugars, thereby regulating the body's blood sugar level.

[0112] Currently, the main clinical hypoglycemic drug acarbose is an α-glucosidase inhibitor. It can produce competitive inhibition with α-glucosidase, thereby preventing the hydrolysis of 1,4-glycosidic bonds and achieving the effect of lowering blood sugar.

[0113] 3 Experimental reagents and instruments

[0114]

[0115] 4 Experimental methods

[0116] 4.1 α-Glucosidase Inhibition Ability Assay

[0117] Reference, the pNPG method was used to determine the α-glucosidase inhibitory activity. Use a pipette to accurately draw 110 μL of phosphate buffer (pH = 6.8) into the microwells of a 96-well plate, add 20 μL of sample solution and 20 μL of α-glucosidase solution (2U / mL), mix well, and incubate in a 37°C incubator for 10 minutes. Continue to add 20 μL of substrate pNPG (10 mmol / L), and the system reacts at 37°C for 20 minutes. Then, add 80 μL of sodium carbonate (0.1 mol / L) to terminate the reaction, and use acarbose (0.5 mg / mL) as the positive control group, and repeat the above experimental operation. Use an enzyme reader to measure its absorbance at 405 nm, and calculate the α-glucosidase inhibition rate according to the formula:

[0118] Sample absorbance A1; replace the test solution with an equal volume of distilled water and measure its absorbance A0; replace the α-glucosidase solution with an equal volume of sodium phosphate buffer and measure its absorbance A2; replace the test solution and α-glucosidase solution with equal volumes of distilled water and sodium phosphate buffer respectively and measure their absorbance A3. Calculate the inhibition rate using the following formula.

[0119]

[0120] 5 Experimental data and processing

[0121] 1 2 3 average value Probiotics stock solution 62.00％ 50.04％ 50.74％ 54.26％ Acarbose 66.50％ 68.36％ 58.28％ 68.38％

[0122] 6 Experimental results

[0123] Acarbose is an α-glucosidase inhibitor and one of the main clinical drugs for the treatment of diabetes. Acarbose was also selected as a positive control in this experiment. The α-glucosidase inhibition rate of the probiotic stock solution in this experiment was 54.26%. Compared with the α-glucosidase inhibition rate of acarbose in this experiment of 68.38%, the probiotic stock solution has the effect of lowering blood sugar. (Taking the α-glucosidase inhibition rate of acarbose as the benchmark value, the α-glucosidase inhibition rate of the probiotic stock solution was 79.35%.)

[0124] Acarbose and α-glucosidase have an obvious competitive inhibition relationship, so the final inhibition rate is directly related to the enzyme activity and addition amount of α-glucosidase. The low inhibition rate may also be due to the different binding sites of the inhibitors caused by the different enzyme structures from different sources. In addition, the inhibitory activity of α-glucosidase is closely related to its source, so the α-glucosidase inhibition rate obtained in this experiment is not very comparable with the α-glucosidase inhibition rate of other experiments.

[0125] The following is the test result of the probiotic stock solution components of the present invention:

[0126]

[0127]

[0128] The above test results show that the present invention produces folic acid and SOD during the preparation and fermentation process. Folic acid is a water-soluble vitamin used to treat folic acid deficiency caused by various reasons and megaloblastic anemia caused by folic acid deficiency. It can be used for preventive treatment before pregnancy and in the first three months of pregnancy to reduce the risk of fetal neural tube defects. It can also be used to treat folic acid deficiency caused by chronic hemolytic anemia. SOD is a superoxide dismutase, which is a type of enzyme that can catalyze superoxide anion free radicals (O2 - ) is an enzyme that dismutates into H2O2 and O2, which has antioxidant and anti-aging effects. Its mechanism of action is mainly to remove superoxide anion free radicals that are harmful to the body. It can also be used to treat diseases caused by superoxide free radicals such as oxygen poisoning, acute inflammation, various autoimmune diseases, radiation sickness and senile cataracts, etc., and has unique therapeutic effects.

[0129] Compared with existing probiotic products, the probiotic stock solution provided by the present invention is more convenient to eat and store in liquid state, has the functions of lowering uric acid and blood sugar, and can produce folic acid and SOD during the preparation and fermentation process, thereby enriching the efficacy of probiotic products, being safe, convenient, and having rich efficacy.

[0130] The above specific examples are used to illustrate the present invention, which is only used to help understand the present invention and is not intended to limit the present invention. For those skilled in the art, according to the concept of the present invention, some simple deductions, modifications or substitutions can be made.

Claims

1. A probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar, characterized by: The probiotic stock solution comprises fermentation liquid of Bifidobacterium animalis XIMC-002, fermentation liquid of Lactobacillus paracasei XIMC-001, fermentation liquid of Lactobacillus casei XIMC-003, fermentation liquid of Lactobacillus fermentum XIMC-009, fermentation liquid of Lactobacillus rhamnosus XIMC-6 and fermentation liquid of Lactobacillus reuteri XIMC-30.

2. The probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 1, characterized in that: The animal Bifidobacterium XIMC-002 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22522; The Lactobacillus paracasei XIMC-001 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number of CGMCC NO.22521; The Lactobacillus casei XIMC-003 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22524; The fermented Lactobacillus XIMC-009 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22525; The Lactobacillus rhamnosus XIMC-6 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on November 22, 2021, with the deposit number CGMCC NO.23954; The Lactobacillus reuteri XIMC-30 was deposited in the General Microbiology Center of the China Microorganism Culture Collection Administration on May 22, 2023, with the deposit number CGMCC NO.27396.

3. The probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 1, characterized in that: The probiotic stock solution also contains Lactobacillus plantarum XIMC-005 fermentation liquid and Lactobacillus gestatum XIMC-011 fermentation liquid.

4. The probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 3, characterized in that: The Lactobacillus plantarum XIMC-005 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22526; The formative Lactobacillus XIMC-011 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on May 14, 2021, with the deposit number CGMCC NO.22523.

5. A method for preparing a probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar, characterized in that: The method comprises: Using a fermentation medium containing beans to culture various strains, the various strains include Bifidobacterium animalis XIMC-002, Lactobacillus paracasei XIMC-001, Lactobacillus casei XIMC-003, Lactobacillus fermentum XIMC-009, Lactobacillus rhamnosus XIMC-6 and Lactobacillus reuteri XIMC-30, and fermenting to obtain fermentation liquid; Mix all the fermentation liquids and stir them evenly to obtain a mixed liquid; The mixed liquid is divided into small strips to obtain the finished product, which is then refrigerated for storage.

6. The method for preparing the probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 5, characterized in that: The various strains also include Lactobacillus plantarum XIMC-005 and Lactobacillus formatus XIMC-011.

7. The method for preparing the probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 5 or 6, characterized in that: The fermentation medium contains beans and is used to grow various strains, including: The strain was inoculated into MRS culture solution and placed in an incubator for culture to obtain seed solution; Sterilizing fermentation media containing legumes; The seed liquid is poured into a sterilized fermentation medium containing beans and water, and fermented to obtain a fermentation liquid.

8. The method for preparing the probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 7, characterized in that: The formula of MRS culture medium is: Potassium dihydrogen phosphate 0.2-0.4%; Diammonium hydrogen phosphate 0.1~0.3%; Sodium acetate 0.5-0.8%; Magnesium sulfate 0.02-0.04%; Manganese sulfate 0.003~0.007%; Tween 80 0.01~0.05%; The rest is water.

9. The method for preparing the probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 8, characterized in that: The formulation of the fermentation medium containing legumes is: Beans 2-3%; Yeast extract powder 0.4-0.8%; Glucose 2-3%; The rest is water.

10. The method for preparing the probiotic stock solution that produces folic acid and SOD and has the functions of lowering uric acid and blood sugar according to claim 9, characterized in that: The beans are selected from soybeans, black beans, adzuki beans and mung beans.

Images